Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with biweekly SOX as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR1800018854Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-free survival. Started Oct 2018; status: recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800018854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018854.